TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer & Retirement of Daniel A. Cartwright a...
June 01 2020 - 5:50AM
Business Wire
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s
healthcare company, announced today the appointment of James C.
D’Arecca as the Company’s Chief Financial Officer, effective June
1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has
retired from his position as the Company’s Chief Financial Officer,
also effective June 1, 2020. Mr. Cartwright will remain with the
Company as an advisor for a transitional period. Mr. D’Arecca joins
TherapeuticsMD with broad experience in corporate and operational
finance, most recently as Senior Vice President and Chief
Accounting Officer of Allergan plc.
“I can’t imagine a more exciting time to join TherapeuticsMD,”
says Mr. D’Arecca. “Having spent time in the women’s health market
while at Allergan, I believe that TherapeuticsMD is well positioned
to redefine women’s healthcare with a full portfolio of new and
innovative products. I look forward to working with all my new
colleagues as we position the company and our portfolio for
continued growth.”
“I am thrilled that James has agreed to join TherapeuticsMD,”
said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD.
“James is a seasoned executive with a wealth of experience
supporting high-growth commercially-focused pharmaceutical
businesses and has a history of providing strong financial
discipline and leadership. We look forward to adding James to our
executive team. I believe he will help us continue our drive to
build long-term shareholder value."
“I also want to congratulate Dan on his retirement,” said Mr.
Finizio. “We want to thank him for nine years of outstanding
service and dedication to our Company.”
About James C. D’Arecca
Prior to joining TherapeuticsMD, Mr. D’Arecca served as the
Senior Vice President and Chief Accounting Officer of Allergan plc
(formerly known as Actavis plc) from August 2013 until its merger
with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the
finance team through Allergan’s journey from a generics
manufacturer (Watson/Actavis) to a leading global pharmaceutical
company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where
he served as its Chief Accounting Officer. Prior to Bausch &
Lomb, he served in various roles of increasing responsibility at
Merck & Co. Inc. and Schering-Plough in finance and business
development. He also spent 13 years with PricewaterhouseCoopers,
with an industry focus on pharmaceuticals, medical devices, and
consumer products. Mr. D'Arecca earned his MBA from Columbia
University, his B.S. in accounting from Rutgers University, and is
a Certified Public Accountant.
About TherapeuticsMD
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The Company is
committed to advancing the health of women and championing
awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on
Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the Company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the Company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the Company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the Company’s filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, and include
the following: the Company’s ability to protect the intellectual
property related to its products; the effects of the COVID-19
pandemic; the Company’s ability to maintain or increase sales of
its products; the Company’s ability to develop and commercialize
IMVEXXY®, ANNOVERA®, BIJUVA® and its hormone therapy drug
candidates and obtain additional financing necessary therefor;
whether the Company will be able to comply with the covenants and
conditions under its term loan facility, including the conditions
to draw an additional tranche thereunder and whether the lender
will make such tranche available; the potential of adverse side
effects or other safety risks that could adversely affect the
commercialization of the Company’s current or future approved
products or preclude the approval of the Company’s future drug
candidates; whether the FDA will approve the efficacy supplement
for the lower dose of BIJUVA; the Company’s ability to protect its
intellectual property, including with respect to the Paragraph IV
notice letters the Company received regarding IMVEXXY and BIJUVA;
the length, cost and uncertain results of future clinical trials;
the Company’s reliance on third parties to conduct its
manufacturing, research and development and clinical trials; the
ability of the Company’s licensees to commercialize and distribute
the Company’s products; the ability of the Company’s marketing
contractors to market ANNOVERA; the availability of reimbursement
from government authorities and health insurance companies for the
Company’s products; the impact of product liability lawsuits; the
influence of extensive and costly government regulation; the
volatility of the trading price of the Company’s common stock and
the concentration of power in its stock ownership. PDF copies of
the Company’s historical press releases and financial tables can be
viewed and downloaded at it website:
www.therapeuticsmd.com/pressreleases.aspx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200601005241/en/
Investor Contact Nichol
Ochsner Vice President, Investor Relations 561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2024 to May 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From May 2023 to May 2024